Article

Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemia

2025-09-30

Abstract excerpt

<h4> ABSTRACT </h4> Disease persistence and therapeutic resistance remain a significant challenge in chronic myelogenous leukemia (CML). Here, we evaluated the therapeutic impact of SOS1 inhibition by its specific pharmacological inhibitor BI-3406 as single-agent or in combination with BCR/ABL tyrosine kinase inhibitors (TKI) like imatinib in preclinical models of CML including p210 BCR/ABL mice, human CML cell...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9e92fa36-cc47-5124-99b2-bd8ff0e54d9a
DOI: 10.1101/2025.09.29.679122

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemiaDOI 10.1101/2025.09.29.679122Read

Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous LeukemiaSemantic proximity Read

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia.Semantic proximity Read

SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers.Semantic proximity Read

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cellsSemantic proximity Read

Pharmacological SOS1 inhibitor BI-3406 demonstrates <i>in vivo</i> anti-tumor activity comparable to SOS1 genetic ablation in KRAS mutant tumorsSemantic proximity Read

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a reviewSemantic proximity Read

Chronic myeloid leukemia stem cells: targeting therapeutic implicationsSemantic proximity Read

Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.Semantic proximity Read

Leukemia stem cells: the root of chronic myeloid leukemiaSemantic proximity Read

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.Semantic proximity Read

Molecular biology of bcr-abl1–positive chronic myeloid leukemiaSemantic proximity Read

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.Semantic proximity Read